BEVAZAME Trademark

Trademark Overview

On Monday, June 15, 2015, a trademark application was filed for BEVAZAME with the United States Patent and Trademark Office. The USPTO has given the BEVAZAME trademark a serial number of 86662892. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 18, 2019. This trademark is owned by Pfizer Inc.. The BEVAZAME trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, preparations for use in dermatology, smoking cessation preparations, and tissue repair preparations; vaccines for human use
bevazame

General Information

Serial Number86662892
Word MarkBEVAZAME
Filing DateMonday, June 15, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 18, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 15, 2015

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, preparations for use in dermatology, smoking cessation preparations, and tissue repair preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 18, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, March 18, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 18, 2019ABANDONMENT - NO USE STATEMENT FILED
Tuesday, July 10, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, July 7, 2018EXTENSION 5 GRANTED
Friday, June 29, 2018EXTENSION 5 FILED
Thursday, July 5, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, June 29, 2018TEAS EXTENSION RECEIVED
Tuesday, February 6, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 2, 2018EXTENSION 4 GRANTED
Friday, February 2, 2018EXTENSION 4 FILED
Friday, February 2, 2018TEAS EXTENSION RECEIVED
Tuesday, August 1, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 28, 2017EXTENSION 3 GRANTED
Friday, July 28, 2017EXTENSION 3 FILED
Friday, July 28, 2017TEAS EXTENSION RECEIVED
Thursday, January 12, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 10, 2017EXTENSION 2 GRANTED
Tuesday, January 10, 2017EXTENSION 2 FILED
Tuesday, January 10, 2017TEAS EXTENSION RECEIVED
Thursday, August 4, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 2, 2016EXTENSION 1 GRANTED
Tuesday, August 2, 2016EXTENSION 1 FILED
Tuesday, August 2, 2016TEAS EXTENSION RECEIVED
Tuesday, February 9, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 15, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 15, 2015PUBLISHED FOR OPPOSITION
Wednesday, November 25, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, November 9, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, November 6, 2015ASSIGNED TO LIE
Monday, September 28, 2015ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 28, 2015TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, September 28, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 28, 2015EXAMINER'S AMENDMENT ENTERED
Monday, September 28, 2015NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, September 28, 2015EXAMINERS AMENDMENT E-MAILED
Monday, September 28, 2015EXAMINERS AMENDMENT -WRITTEN
Friday, September 25, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 25, 2015NON-FINAL ACTION E-MAILED
Friday, September 25, 2015NON-FINAL ACTION WRITTEN
Wednesday, September 23, 2015ASSIGNED TO EXAMINER
Thursday, June 18, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, June 18, 2015NEW APPLICATION ENTERED IN TRAM

Related Keywords

bevazame preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases